(Q38387687)

2 September 2017

1 reference

title

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety (English)

1 reference

relapsing-remitting multiple sclerosis

2 September 2017

0 references

1 reference

1 reference

2

Bernd C Kieseier

1 reference

2 September 2017

Duvyanshu Dubey

1

1 reference

2 September 2017

Hans P Hartung

3

1 reference

2 September 2017

Bernhard Hemmer

4

1 reference

2 September 2017

Clemens Warnke

5

1 reference

2 September 2017

Til Menge

6

1 reference

2 September 2017

William A Miller-Little

7

1 reference

2 September 2017

Olaf Stuve

8

1 reference

2 September 2017

publication date

1 April 2015

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

2 September 2017

published in

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

339-346

1 reference

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Current and future therapies targeting the immune system in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Oral treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Revised estimate of the prevalence of multiple sclerosis in the united states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Temporal trends in the incidence of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

How common are the "common" neurologic disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

The role of CD4 T cells in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

B cells regulate autoimmunity by provision of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Mode of action and clinical studies with fumarates in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Glutathione regulates susceptibility to oxidant-induced mitochondrial DNA damage in human lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Phytochemical induction of cell cycle arrest by glutathione oxidation and reversal by N-acetylcysteine in human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Dimethylfumarate impairs melanoma growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025755

10.1586/14737175.2015.1025755

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference